What is Elanco Animal Health Inc.'s market cap?

Elanco Animal Health Inc. (ELAN) has a market capitalization of $12.3B and trades on NYSE.

What is Elanco Animal Health Inc.'s revenue and profitability?

Elanco Animal Health Inc. generated $4.9B in trailing twelve-month revenue with a net loss of $242.0M, representing a net margin of -4.9%. Gross margin stands at 55.1%, with free cash flow of $315.0M. These figures are based on the Q1 2026 filing.

Who are Elanco Animal Health Inc.'s competitors?

Elanco Animal Health Inc.'s key competitors include Zoetis Inc., Merck Animal Health, Phibro Animal Health Corporation Class A, and others. These companies compete in similar markets and product categories.

Who does Elanco Animal Health Inc. partner with?

Elanco Animal Health Inc.'s notable partners include Cencora, Inc..

What subsidiaries does Elanco Animal Health Inc. have?

Elanco Animal Health Inc.'s subsidiaries include Bayer Animal Health.

Where is Elanco Animal Health Inc. headquartered?

Elanco Animal Health Inc. is headquartered in United States of America and employs approximately 9,800 people. It has been publicly traded since 2018.

Elanco Animal Health Inc.

ELAN

Elanco is a global leader in animal health that develops, manufactures, and markets products for both pets and farm animals.

Market cap

$12.33B+69.6%

Revenue$4.9B+10.5%

Net income-$242.0M-164%

Free cash flow$315.0M-9.2%

EPS (diluted)-$0.50-166%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 6, 2026

Revenue$1.4BBeat by $93.9M EPS$0.40Beat by $0.06

Read the full report

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$1.3B

EPS estimate$0.28

Financials

Q1 2026

Income statement

See full

Revenue$1.4B+14.9%

Gross profit$785.0M+14.8%

Net income$57.0M-14.9%

EPS (diluted)$0.11-15.4%

Balance sheet

See full

Cash & equivalents$428.0M-12.1%

Total debt$4.3B-1.7%

Total equity$6.5B+2.3%

Total assets$13.2B+2.2%

Cash flow

See full

Operating cash flow$13.0M+425%

CapEx$51.0M-21.5%

Free cash flow-$38.0M+44.9%

Valuation & ratios

Valuation

See full

Market cap$12.33B+69.6%

Enterprise value$16.22B+44.1%

P/S2.5×+0.9×

Profitability

See full

Gross margin55.1%+0.2pp

Net margin-4.9%-13.6pp

FCF margin6.4%-1.4pp

Returns & leverage

See full

Return on equity-3.8%-9.9pp

Debt / equity0.7×0.0×

Current ratio2.2×-0.6×

Segments

By product

See full

Pet Health$710.0M+11.8%

Cattle$316.0M+16.2%

Poultry$230.0M+21.7%

Swine$96.0M+12.9%

Contract Manufacturing$19.0M+58.3%

By segment

See full

Reportable Segment$1.4B+14.9%

Competitors

By market cap

Merck & Co.$311.17B+53.1%

Zoetis$31.5B-55.6%

Tractor Supply Company$15.5B-46.4%

Elanco Animal Health Inc.$12.3B+69.6%

Neogen$2.0B+74.2%

Phibro Animal Health$1.3B+15.9%

PetMed Express$42.7M-37.1%

Jaguar Health$2.0M-42.3%

By revenue growth

Phibro Animal Health+26.0%

Elanco Animal Health Inc.+10.5%

Tractor Supply Company+4.6%

Merck & Co.+2.9%

Zoetis+2.6%

Neogen-3.9%

By net margin

Zoetis27.79%+0.9pp

Merck & Co.13.59%-13.7pp

Tractor Supply Company12.46%+5.2pp

Phibro Animal Health6.35%+3.7pp

Elanco Animal Health Inc.-4.95%-13.6pp

Neogen-69.94%-16.4pp

Profile

Elanco is a global leader in animal health that develops, manufactures, and markets products for both pets and farm animals. The company provides a diverse portfolio of medicines, vaccines, and nutritional supplements designed to prevent and treat disease across more than 90 countries. Its value proposition centers on improving animal health to enhance food system security and the well-being of pets and their owners.

Competitive position

A leading global player in the animal health industry with a diverse, durable portfolio and a significant R&D pipeline focused on high-impact innovation.

GeographiesUnited States, Brazil, United Kingdom, China, European Union, Australia, Japan

Customer segmentsVeterinary clinics, Livestock producers, Pet owners, Agricultural enterprises

Business modelManufacturing, Research and Development, B2B, B2B2C

SuppliersActive pharmaceutical ingredient (API) suppliers, Contract manufacturing organizations (CMOs), Raw material providers, Third-party R&D partners

CustomersVeterinary distributors, Retailers, E-commerce platforms, Commercial farm operations

CountryUnited States of America

Listed2018

Employees9.8K

CEOJeffrey N. Simmons

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteelanco.com

FilingsSEC EDGAR

Ask your AI about Elanco Animal Health Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Elanco Animal Health Inc.'s market cap?: Elanco Animal Health Inc. (ELAN) has a market capitalization of $12.3B and trades on NYSE.
What is Elanco Animal Health Inc.'s revenue and profitability?: Elanco Animal Health Inc. generated $4.9B in trailing twelve-month revenue with a net loss of $242.0M, representing a net margin of -4.9%. Gross margin stands at 55.1%, with free cash flow of $315.0M. These figures are based on the Q1 2026 filing.
Who are Elanco Animal Health Inc.'s competitors?: Elanco Animal Health Inc.'s key competitors include Zoetis Inc., Merck Animal Health, Phibro Animal Health Corporation Class A, and others. These companies compete in similar markets and product categories.
Who does Elanco Animal Health Inc. partner with?: Elanco Animal Health Inc.'s notable partners include Cencora, Inc..
What subsidiaries does Elanco Animal Health Inc. have?: Elanco Animal Health Inc.'s subsidiaries include Bayer Animal Health.
Where is Elanco Animal Health Inc. headquartered?: Elanco Animal Health Inc. is headquartered in United States of America and employs approximately 9,800 people. It has been publicly traded since 2018.